Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

Open access
Paz-Ares, L., Tan, E.-H., O’Byrne, K., Zhang, L., Hirsh, V., Boyer, M., Yang, J.C.-H., Mok, T., Lee, K.H., Lu, S., Shi, Y., Lee, D.H., Laskin, J., Kim, D.-W., Laurie, S.A., Kölbeck, K., Fan, J., Dodd, N., Märten, A., Park, K. · 2017 · Annals of Oncology

Abstract

Background: In LUX-Lung 7, the irreversible ErbB family blocker, afatinib, significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and objective response rate (ORR) versus gefitinib in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Here, we present primary analysis of mature overall survival (OS) data. Patients and methods: LUX-Lung 7 assessed afatinib 40 mg/day versus gefitinib 250 mg/day in treatment-naïve patients with stage IIIb/IV NSCLC and a common EGFR mutation (exon 19 deletion/L858R). Primary OS analysis was planned after ∼213 OS events and ≥32-month follow-up. OS was analysed by a Cox proportional hazards model, stratified by EGFR mutation type and baseline brain metastases. Results: Two-hundred and twenty-six OS events had occurred at the data cut-off (8 April 2016). After a median follow-up of 42.6 months, median OS (afatinib versus gefitinib) was 27.9 versus 24.5 months [hazard ratio (HR) = 0.86, 95% confidence interval (CI) 0.66‒1.12, P = 0.2580]. Prespecified subgroup analyses showed similar OS trends (afatinib versus gefitinib) in patients with exon 19 deletion (30.7 versus 26.4 months; HR, 0.83, 95% CI 0.58‒1.17, P = 0.2841) and L858R (25.0 versus 21.2 months; HR 0.91, 95% CI 0.62‒1.36, P = 0.6585) mutations. Most patients (afatinib, 72.6%; gefitinib, 76.8%) had at least one subsequent systemic anti-cancer treatment following discontinuation of afatinib/gefitinib; 20 (13.7%) and 23 (15.2%) patients received a third-generation EGFR tyrosine kinase inhibitor. Updated PFS (independent review), TTF and ORR data were significantly improved with afatinib. Conclusion: In LUX-Lung 7, there was no significant difference in OS with afatinib versus gefitinib. Updated PFS (independent review), TTF and ORR data were significantly improved with afatinib. Clinicaltrials.gov identifier: NCT01466660.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdw611

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Overall survival. Kaplan–Meier curve (A) and forest plot of pre-specified subgroup analyses (B). CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; HR, hazard ratio.
Figure 1 Overall survival. Kaplan–Meier curve (A) and forest plot of pre-specified subgroup analyses (B). CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; HR, hazard ratio.CC BY-NC · PubMed Central
Figure 2 Overall survival in patients with common EGFR mutations. Patients with exon 19 deletion (A) and patients with L858R mutation (B). CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio.
Figure 2 Overall survival in patients with common EGFR mutations. Patients with exon 19 deletion (A) and patients with L858R mutation (B). CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio.CC BY-NC · PubMed Central
Figure 3 Overall survival in patients subsequently treated with a third-generation EGFR TKI following discontinuation of study treatment. CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; TKIs, tyrosine kinase inhibitors.
Figure 3 Overall survival in patients subsequently treated with a third-generation EGFR TKI following discontinuation of study treatment. CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; TKIs, tyrosine kinase inhibitors.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Research works printed but not linked: 2

  1. Yoshioka, 2014, J Clin Oncol, 32 (Suppl. 15)
  2. Yang, 2015, A Randomized Controlled Trial of Erlotinib versus Gefitinib in Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations (CTONG0901), J Thorac Oncol, 10, S321

Cited by

See all 524

Metadata

Authors
Paz-Ares, L., Tan, E.-H., O’Byrne, K., Zhang, L., Hirsh, V., Boyer, M., Yang, J. C.-H., Mok, T., Lee, K. H., Lu, S., Shi, Y., Lee, D. H., Laskin, J., Kim, D.-W., Laurie, S. A., Kölbeck, K., Fan, J., Dodd, N., Märten, A., & Park, K.
Affiliations
  • Universidad Complutense de Madrid (ES)
  • National Cancer Centre Singapore (SG)
  • Sun Yat-sen University (CN)
  • McGill University (CA)
  • Chris O’Brien Lifehouse (AU)
  • National Taiwan University (TW)
  • Chinese University of Hong Kong (HK)
  • Chungbuk National University (KR)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Asan Medical Center (KR)
  • BC Cancer Agency (CA)
  • Seoul National University (KR)
  • Ottawa Hospital (CA)
  • Karolinska University Hospital (SE)
  • Boehringer Ingelheim (United States) (US)
  • Boehringer Ingelheim (United Kingdom) (GB)
  • Boehringer Ingelheim (Germany) (DE)
  • Samsung Medical Center (KR)
Corresponding author
Paz-Ares, L.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2017-02
Volume
28
Issue
2
Pages
270-277
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2587420003
Cited by
524
References
25
Citations by year
2026: 18 · 2025: 22 · 2024: 36 · 2023: 51 · 2022: 69 · 2021: 82 · 2020: 65 · 2019: 72 · 2018: 77 · 2017: 31
FWCI
55.20
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Arrow@dit (Dublin Institute of Technology) (acceptedVersion)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
  • Trinity's Access to Research Output (TARA) (Trinity College Dublin) (submittedVersion, cc-by-nc-sa)
Funders
  • Amgen
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • International Association for the Study of Lung Cancer
  • Celgene
  • Vertex Pharmaceuticals
  • ACEA Biosciences
  • Clovis Oncology
  • AstraZeneca Korea
  • Chinese University of Hong Kong
  • Astellas Pharma
  • Ono Pharmaceutical
  • Genentech
  • Chugai Pharmaceutical
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords
afatinib, gefitinib, EGFR-mutant non-small cell lung cancer, overall survival, exon 19 deletion, L858R mutation, EGFR tyrosine kinase inhibitors, brain metastases, progression-free survival, time to treatment failure, objective response rate, third-generation EGFR tyrosine kinase inhibitors, treatment-naive patients, subgroup analysis
MeSH terms
Gefitinib, Afatinib, Aged, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Quinazolines, Proportional Hazards Models, Treatment Outcome, Kaplan-Meier Estimate, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. https://app.cochat.ai/papers/10.1093/annonc/mdw611
The paper
Paz-Ares, L., Tan, E.-H., O’Byrne, K., Zhang, L., Hirsh, V., Boyer, M., Yang, J. C.-H., Mok, T., Lee, K. H., Lu, S., Shi, Y., Lee, D. H., Laskin, J., Kim, D.-W., Laurie, S. A., Kölbeck, K., Fan, J., Dodd, N., Märten, A., & Park, K. (2017). Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Annals of Oncology. https://doi.org/10.1093/annonc/mdw611

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.